Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Higher Starting Dose of Insulin Glargine in Overweight/Obese T2D
NCT02836704Phase 4Completed
- Sponsor
- Sanofi
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients with at least one episode of hypoglycemia at 16 weeks. Started Sep 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02836704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836704.